FASLG

Across TCGA pan-cancer cohorts, FASLG Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated FASLG data layer compared with 26 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FASLG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FASLG expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

HNSC, BRCA, and LIHC are the cancer types where FASLG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.156	0.710	.002	32	view →
BRCA	DFS	Median	All	0.547	0.950	<.001	28	view →
LIHC	DFS	Median	All	0.064	0.555	<.001	18	view →
LUSC	OS	Median	II,III,IV	0.181	0.742	.007	12	view →
STAD	DFS	Median	III,IV	1.000	0.337	.039	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ESCA	DFS	Median	All	0.146	0.533	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

FASLG–HNSC (OS)

Open the HNSC breakdown →